Provided by Tiger Fintech (Singapore) Pte. Ltd.

IDEAYA Biosciences

21.67
-0.1900-0.87%
Post-market: 21.670.00000.00%16:20 EDT
Volume:780.06K
Turnover:16.94M
Market Cap:1.90B
PE:-6.00
High:22.01
Open:22.00
Low:21.31
Close:21.86
Loading ...

IDEAYA Biosciences (IDYA) Receives a Hold from Leerink Partners

TIPRANKS
·
18 Dec 2024

IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush

Dow Jones
·
17 Dec 2024

IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial

MT Newswires Live
·
17 Dec 2024

BRIEF-Ideaya Announces Idmc Recommendation Of Move-Forward Dose In Part 2A Of Registration-Enabling Trial Of Darovasertib And Crizotinib Combination

Reuters
·
17 Dec 2024

Ideaya announces IDMC recommendation for darovasertib, crizotinib combination

TIPRANKS
·
17 Dec 2024

IDEAYA Biosciences Inc - Targets Phase 3 Study for Uveal Melanoma in First Half of 2025

THOMSON REUTERS
·
17 Dec 2024

IDEAYA Announces Idmc Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L Hla-a2-Negative Metastatic Uveal Melanoma

THOMSON REUTERS
·
17 Dec 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

PR Newswire
·
17 Dec 2024

Promising Pipeline and Strategic Partnerships Drive Buy Rating for IDEAYA Biosciences

TIPRANKS
·
17 Dec 2024

IDEAYA Biosciences: Promising Pipeline and Strong Financials Make for a Buy Recommendation

TIPRANKS
·
17 Dec 2024

BRIEF-Ideaya Announces Development Candidate Nomination Of Ide251

Reuters
·
16 Dec 2024

IDEAYA Biosciences Inc: Targeting Ind Submission for Ide251 in 2025

THOMSON REUTERS
·
16 Dec 2024

IDEAYA Announces Development Candidate Nomination of Ide251, a Potential First-in-Class Kat6/7 Dual Inhibitor Targeting 8P11 Amplification Tumors in Breast and Lung Cancers

THOMSON REUTERS
·
16 Dec 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

PR Newswire
·
16 Dec 2024

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

Simply Wall St.
·
16 Dec 2024